GLOBAL LEADERS IN GENOMIC MEDICINE MEETING

Indian Perspective

S. Sinha Advisor Department of Biotechnology Ministry of Science and Technology

STRUCTURE OF THE PRESENTATION

- Strategy: Benefits and targets in Indian Context
- Implementation of Genomic Medicine in India : DBT initiatives
- Hurdles in Implementation
- Collaborations

Strategy: Benefits and targets in Indian Context

- Implementation of Genomic Medicine in India : DBT initiatives
- Hurdles in Implementation
- Collaborations



AREAS LIKELY TO BE BENEFITTED



- Strategy: Benefits and targets in Indian Context
- Implementation of Genomic Medicine in India : DBT initiatives
- Hurdles in Implementation
- Collaborations

INFRASTRUCTURE DEVELOPMENT AT INSTITUTES FOR ADVANCED GENOMIC RESEARCH AND PHARMACOGENOMICS IMPLEMENTATION



GENETIC CATALOGUING OF ETHNIC GROUPS

Data coordination

1. Clinicians

- 2. Molecular Geneticists
- 3. Anthropologists

Creation of baseline data on various ethnic groups for disease susceptibility

PROMOTING TRANSLATIONAL RESEARCH

- ✓ Diagnostic kits
- Vaccines using reverse genetics
- ✓ Molecular tool for surveillance
- Control of Newcastle disease by siRNA mediated inhibition of virus
- Disease based sequence analysis

PRE-NATAL CARE

- Maternal risk and pregnancy risk prediction
- Fetal Risk Prediction and anomaly diagnosis
- initiating programs involving Developmental biology, Pregnancy Risks and Pre-term Birth
- ✓ Setting up of Genetic Clinics

CANCER GENOMICS

- ✓ Genomics and Epigenomics of Cancer
- ✓ Transcriptomics of Cancer
- ✓ NIBMG is a part of the International Cancer Genome Consortium (Oral Cancer)

OTHER AREAS

- Strengthening of bioinformatics network by creating Genome Mirror sites
- Regulatory guidelines for Genomic Medicine techniques, research activities and harmonisation with international ethical guidelines (National Bioethics Commitee- DBT nodal agency).
- ✓ Manpower training in various aspects of Genomic Medicine
- Establishment of transformed cell line for rare and genetic diseases and their genetic analysis
- Funding of research in areas like genotype-phenotype correlation in oxidative stress related gene polymorphisms, DNA repair proteins, mutation screening in Congenital Adrenal Hyperplasia, finding drug targets in *P.falciparum*, diagnosis using pharmacogenetic tools, biomarkers, cancer genomics

- Strategy: Benefits and targets in Indian Context
- Implementation of Genomic Medicine in India : DBT initiatives
- Hurdles in Implementation
- Collaborations

COMMON BARRIERS IN IMPLEMENTATION

- ✓ Handling large dataset
- Evidence for health treatments are based on research goals
- ✓ Research waste due to lack of expertise
- Lack of regulatory guidelines
- ✓ Incidental findings majorly
- Lack of knowledge in primary healthcare providers
- ✓ Need for better technologies
- ✓ Large dataset for patients and lack of translation/interpretation



✓ Funding and political will

- Strategy: Benefits and targets in Indian Context
- Implementation of Genomic Medicine in India : DBT initiatives
- Hurdles in Implementation
- Collaborations

POSSIBLE AVENUES FOR COLLABORATION

- Streamlining of guidelines for implementation and preclinical/clinical trials
- Use of traditional knowledge and integration into modern genetics
- Cloudsourcing for translation of genetic data
- Development of new methods of disease classification based on recently discovered genetic principles
- Building community interest and participation
- ✓ Building data sharing capabilities
- Unify strategies ongoing at various places
- ✓ Set up biobanking facilities
- ✓ Training of Manpower
- Building study cohorts



Over to

PARTHA MAJUMDER National Institute of Biomedical Genomics Kalyani, India

Genetic Epidemiology of Cancer in India

CANCER ATLAS OF INDIA

Indian Council of Medical Research (*in collaboration with WHO*)

1980-2000

Districtwise Minimum Age Adjusted Incidence Rate Per 100,000 TONGUE (ICD10,C01-C02) - Males



Districtwise Minimum Age Adjusted Incidence Rate Per 100,000 MOUTH (ICD10, C03-C06) - Males



Districtwise Minimum Age Adjusted Incidence Rate Per 100,000 TONSIL (ICD10, C09) - Males



Districtwise Minimum Age Adjusted Incidence Rate Per 100,000 OROPHARYNX (ICD10, C10) - Males



Institutions involved in Cancer Research

Clinical cum Basic

- 1. All India Institute of Medical Sciences (AIIMS), New Delhi
- 2. Kidwai Memorial Institute of Oncology (KMIO), Bengaluru
- 3. Tata Memorial Hospital (TMH), Mumbai
- 4. Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai
- 5. Cancer Institute (WIA), Chennai
- 6. Rajiv Gandhi Center For Biotechnology (RGCB), Thiruvananthapuram
- 7. Institute of Cytology & Preventive Oncology (ICPO), Noida

Basic Biology of Cancers

- 1. National Centre for Cell Sciences (NCCS), Pune
- 2. National Brain Research Centre (NBRC), Manesar
- 3. National Centre for Biological Sciences (NCBS), Bengaluru
- 4. National Institute of Immunology (NII), New Delhi
- 5. Mazumdar Shaw Cancer Center (MSCC), Bengaluru
- 6. Indian Institute of Science (IISc), Bengaluru
- 7. Institute of Life Sciences, Bhubaneshwar

Adjunct Facilities

- 1. C-CAMP, Bengaluru
- 2. Institute of Bioinformatics, Bengaluru
- 3. C-DAC, Pune

Slide Courtesy: Dr. Bindu Dey, Adviser, DBT

Focus of Research

Based on Disease-burden

- Oral/Head & Neck cancer
- Cervical cancer
- Breast cancer sp. triple-negative, pre-menopausal cancer

Uniqueness to India

- Nasopharyngeal cancer- NER
- Gall Bladder cancer- Along Ganges belt; mostly in women
- Gastric cancer from Nagaland (Naga cancer)/Kashmir

Competence availability

- Gliomas (funding primarily by CSIR)
- Leukemias

Work initiated

- Lung cancer
- Pancreatic cancer

Slide Courtesy: Dr. Bindu Dey, Adviser, DBT



Lead Jurisdiction	Funding Organization	Tumor Type				
Australia	National Health and Medical Research Council	Pancreatic Cancer Ductal adenocarcinoma				
		Ovarian Cancer Serous adenocarcinoma				
Canada	Ontario Institute for Cancer Research Ontario Ministry of Research and Innovation	Pancreatic Cancer Ductal adenocarcinoma				
China	Chinese Cancer Genome Consortium	Sastric Cancer Intestinal- and Diffuse-type				
European Union/France	European Commission FP7	Renal Cancer Renal cell carcinoma Focus on but not limited to clear cell subtype	ts			
European Union/ United Kingdom	European Commission FP7	Breast Cancer Subtypes defined by an amplification of ER+ HER- ductal-type	je c			
France	Institut National du Cancer	Breast Cancer HER2 positive	L O			
		Liver Cancer Hepatocellular carcinoma Secondary to alcohol and adiposity	ъ Б			
Germany	Federal Ministry of Education and Research German Cancer Aid	Pediatric Brain Tumors Medulloblastoma	E			
Department of Biotechnology, 🔅 Oral Cance						
Ministry of Science & Technology Gingivobuccal						
	Ranari Winistry of Education, oniversity and Rese	rare pancreatic exocrine tumors	<u> </u>			
Japan	RIKEN National Institute of Biomedical Innovation	Liver Cancer Hepatocellular carcinoma Virus associated	JCe			
Spain	Spanish Ministry of Science and Innovation	Chronic Lymphocytic Leukemia CLL with mutated and unmutated IgVH	ja j			
United Kingdom	Wellcome Trust Breakthrough Breast Cancer	Breast Cancer Triple Negative/Lobular/Other				
United States	National Institutes of Health	O Brain Cancer Glioblastoma multiforme	Ŭ			
		Ovarian Cancer Serous cystadenocarcinoma	1			
		Lung Cancer Squamous cell carcinoma Adenocarcinoma				

ICGC Cancer Genome Projects

TCGA Projects

Leukemia Acute myeloid leukemia

Colon Cancer

Squamous Cell Carcinoma of the Oral Cavity: Epidemiological Features

- 8th most common cancer
- ~260,000 new cases annually
- 2/3rd in developing countries
- 128,000 deaths annually

• Accounts for $\sim 1/3^{rd}$ of all tobacco-related cancers in India.

Site Distribution of Oral Cancer



Slide courtesy: Dr. Anil D'Cruz, Tata Memorial Hospital, Mumbai

The Hazardous Combo



Slide courtesy: Dr. Anil D'Cruz, Tata Memorial Hospital, Mumbai

GENES SIGNIFICANTLY MUTATED

Gene	p-value		
CASP8	< 10 ⁻¹³		
TP53	< 10 ⁻¹³		
FAT1	4.10 x 10 ⁻¹³		
HRAS	3.42 x 10 ⁻⁰⁵		
ARID2	1.85 x 10 ⁻⁰⁴		
TRPM3	1.84 x 10 ⁻⁰³		
UNC13C	1.90 x 10 ⁻⁰³		
USP9X	2.56 x 10 ⁻⁰³		
MLL4	1.22 x 10 ⁻⁰²		
NOTCH1	1.43 x 10 ⁻⁰²		

Discovery Sample Size = 50 patients Validation Sample Size = 60 patients

Pathways Most Significantly Altered

Description of pathway	No. of patients affected	p-value	% of genes altered in pathway
p53 signaling pathway	36	4.87E-09	41.2
Apoptosis	37	5.21E-09	42.0
Viral carcinogenesis	39	2.12E-06	36.7
Neurotrophin signaling			
pathway	40	7.12E-06	41.7
Wnt signaling pathway	39	0.00095	37.7

Profile of 'Significant' Genomic Alterations



CCND1, FADD, CDH6, CDH10, DROSHA, MECOM, NFIB, MMP gene cluster, YAP1



We obtained evidence of whole genome duplication in at least 7 tumor samples (Ploidy > 4n).

Patients Form 3 Groups by the Spectra of Mutations



Patients with Mutations in *MLL4* Have Longer Disease Free Survival



With mutation (GREEN line): 20.4 ± 3.1 months Without mutation (BLUE line): 13.5 ± 0.9 months p=0.047



ARTICLE

Received 6 Sep 2013 | Accepted 5 Nov 2013 | Published 2 Dec 2013

DOI: 10.1038/ncomms3873

OPEN

Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups

India Project Team of the International Cancer Genome Consortium¹